Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy

Nephrology Dialysis Transplantation

Volumn 21, Issue 11, 2006, Pages 3258-3268

  Sester, Urban ^a   Junker, Heike ^a   Hodapp, Tobias ^a   Schütz, Alexandra ^a   Thiele, Bernhard ^b   Meyerhans, Andreas ^a   Kohler H ^a   Sester, Martina ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Institute for Immunogenetics   (Germany)

Author keywords

Bacterial infection; Human; Immunosuppression; Mycobacterium tuberculosis; T cells; Transplantation

Indexed keywords

AZATHIOPRINE; BACTERIAL PROTEIN; BCG VACCINE; CYCLOSPORIN A; EARLY SECRETORY ANTIGENIC TARGET 6; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TUBERCULIN; TUBERKULIN GT 10; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BLOOD ANALYSIS; CELLULAR IMMUNITY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FLOW CYTOMETRY; GERMANY; GRAFT RECIPIENT; HEALTH PROGRAM; HEMODIALYSIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; MYCOBACTERIUM TUBERCULOSIS; OUTPATIENT CARE; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SCREENING TEST; SKIN TEST; T LYMPHOCYTE;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SKIN TESTS; TUBERCULIN; TUBERCULOSIS;

EID: 33750015789     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl416     Document Type: Article

References (31)

1. World Health Organization. Changing history. World health report 2004; 120-125
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 6776-6786
3. Klote MM, Agodoa LY, Abbott K. Mycobacterium tuberculosis infection incidence in hospitalized renal transplant patients in the United States, 1998-2000. Am J Transplant 2004; 4: 1523-1528
4. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729
5. Spence RK, Dafoe DC, Rabin G et al. Mycobacterial infections in renal allograft recipients. Arch Surg 1983; 118: 356-359
6. "EBPG" Expert Group on Renal Transplantation", European Best Practice Guidelines for Renal Transplantation (Part 2). Nephrol Dial Transplant 2002; 17: S39-43
7. Eastwood JB, Corbishley CM, Grange JM. Tuberculosis and the kidney. J Am Soc Nephrol 2001; 12: 1307-1314
8. Kasiske BL, Ramos EL, Gaston RS et al. The evaluation of renal transplant candidates: Clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol 1995; 6: 1-34
9. Apaydin S, Altiparmak MR, Serdengecti K, Ataman R, Ozturk R, Erek E. Mycobacterium tuberculosis infections after renal transplantation. Scand J Infect Dis 2000; 32: 501-505
10. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-247
11. Broekmans JF, Migliori GB, Rieder HL et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775
12. Huebner RE, Schein MF, Bass JB,Jr. The tuberculin skin-test. Clin Infect Dis 1993; 17: 968-975
13. Sester M, Sester U, Gärtner B et al. Levels of virus-specific CD4 T-cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71: 1287-1294
14. Sester M, Sester U, Köhler H et al. Rapid whole blood analysis of virus-specific CD4 and CD8 T cell responses in persistent HIV infection. Aids 2000; 14: 2653-2660
15. Sester M, Sester U, Clauer P et al. Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in haemodialysis patients. Kidney Int 2004; 65: 1826-1834
16. Appay V, Rowland-Jones SL. The assessment of antigenspecific CD8+ T-cells through the combination of MHC class I tetramer and intracellular staining. J Immunol Methods 2002; 268: 9-19
17. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356: 1099-1104
18. Lalvani A, Pathan AA, Durkan H et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T-cells. Lancet 2001; 357: 2017-2021
19. Ewer K, Deeks J, Alvarez L et al. Comparison of T-cell-based assay with tuberculin skin-test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361: 1168-1173
20. Mazurek GH, LoBue PA, Daley CL et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286: 1740-1747
21. Shams H, Weis SE, Klucar P et al. Enzyme-linked Immunospot and Tuberculin Skin Testing to Detect Latent Tuberculosis Infection. Am J Respir Crit Care Med 2005; 172: 1161-1168
22. Chapman AL, Munkanta M, Wilkinson KA et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T-cells. Aids 2002; 16: 2285-2293
23. Sester M, Sester U, Alarcon Salvador S et al. Age-related decrease in adenovirus-specific T cell responses. J Infect Dis 2002; 185: 1379-1387
24. Lalvani A, Pathan AA, McShane H et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T-cells. Am J Respir Crit Care Med 2001; 163: 824-828
25. Richeldi L, Ewer K, Losi M et al. Early diagnosis of subclinical multidrug-resistant tuberculosis. Ann Intern Med 2004; 140: 709-713
26. Ferrara G, Losi M, Meacci M et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005; 172: 631-635
27. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104
28. Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-155
29. Horsburgh CR,Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350: 2060-2067
30. Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med 2001; 345: 189-200
31. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: Impact and implications for management. Clin Infect Dis 1998; 27: 1266-1277